Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 7, 1997, Pages 1579-1583

  Drehobl, Margaret ^a   Bianchi, Patrick ^b   Keyserling, Constance H ^c   Tack, Kenneth J ^c   Griffin, Timothy J ^c  

^a Centre for Health Care   (United States)

^b Southern Drug Research   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFACLOR; CEFDINIR;

ADULT; AGED; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME STABILITY; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA;

EID: 0030804903     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.7.1579     Document Type: Article

References (28)

1. Ashby, B. L. 1991. Treatment of pneumonia: new strategies for changing pathogens. Clin. Ther. 13:637-650.
2. Bartlett, J. G., and L. M. Mundy. 1995. Community-acquired pneumonia. N. Engl. J. Med. 333:1618-1624.
3. Bowton, D. L., and D. A. Bass. 1991. Community-acquired pneumonia: the clinical dilemma. J. Thorac. Imaging 6:1-5.
4. Breiman, R. F., J. C. Butler, F. C. Tenover, J. A. Elliott, and R. R. Facklam. 1994. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 271:1831-1835.
5. Casali, L., M. Voi, C. J. Janssen, K. G. Olovich, and W. H. Dere. 1992. Cefaclor advanced formulation versus cefaclor in the treatment of pneumonia. Clin. Ther. 14:570-577.
6. Center for Drug Evaluation and Research. 1993. COSTART IV - coding symbols for thesaurus of adverse reaction terms, 4th ed. U.S. Department of Health and Human Services, Washington, D.C.
7. Chien, S.-M., P. Pichotta, N. Siepman, and C. K. Chan. 1993. Treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Chest 103:697-701.
8. Cohen, M. A., E. T. Joannides, G. E. Roland, M. A. Meservey, M. D. Huband, M. A. Shapiro, J. C. Sesnie, and C. L. Heifetz. 1994. In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and β-lactamase stability. Diagn. Microbiol. Infect. Dis. 18:31-39.
9. Dark, D. 1991. Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections. Am. J. Med. 91(Suppl. 3A):31S-35S.
10. Fang, G.-D., M. Fine, J. Orloff, D. Arisumi, V. L. Yu, W. Kapoor, J. T. Grayston, S. P. Wang, R. Kohler, R. R. Muder, Y. C. Yee, J. D. Rihs, and R. M. Vickers. 1990. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 69:307-316.
11. Farley, M. M., D. S. Stephens, P. S. Brachman, Jr., R. C. Harvey, J. D. Smith, and J. D. Wenger. 1992. Invasive Haemophilus influenzae disease in adults: a prospective, population-based surveillance. Ann. Intern. Med. 116: 806-811.
12. Garibaldi, R. A. 1985. Epidemiology of community-acquired respiratory tract infections in adults: incidence, etiology, and impact. Am. J. Med. 78(Suppl. 6B):32-37.
13. Gleckman, R. A. 1991. Pneumonia: update on diagnosis and treatment. Geriatrics 46:49-56.
14. Hedlund, J. 1995. Community-acquired pneumonia requiring hospitalisation: factors of importance for the short- and long term prognosis. Scand. J. Infect. Dis. Suppl. 97:6-12.
15. Hyslop, D. L. 1992. Efficacy and safety of loracarbef in the treatment of pneumonia. Am. J. Med. 92(Suppl. 6A):65S-69S.
16. Hyslop, D. L., K. Jacobson, and F. J. Guerra. 1992. Loracarbef (LY163892) versus amoxicillin/clavulanate in bronchopneumonia and lobar pneumonia. Clin. Ther. 14:254-267.
17. Johnson, R. H. 1988. Community-acquired pneumonia: etiology, diagnosis, and treatment. Clin. Ther. 10:568-573.
18. Jones, R. N., M. E. Erwin, and B. B. Gooding. 1992. Interpretive criteria for disk diffusion tests using 5-microgram cefdinir disks with rapidly growing clinical isolates. J. Clin. Microbiol. 30:1022-1023.
19. Klimek, J. J., E. Ajemian, S. Fontecchio, J. Gracewski, B. Klemas, and L. Jimenez. 1983. Community-acquired bacterial pneumonia requiring admission to hospital. Am. J. Infect. Control 11:79-82.
20. Leedom, J. M. 1992. Pneumonia: patient profiles, choice of empiric therapy, and the place of third-generation cephalosporins. Diagn. Microbiol. Infect. Dis. 15:57-65.
21. Marrie, T. J. 1990. Community-acquired pneumonia. Medicine 9:1064-1076.
22. Marrie, T. J. 1994. Community-acquired pneumonia. Clin. Infect. Dis. 18: 501-515.
23. National Committee for Clinical Laboratory Standards. 1990. Performance standards for antimicrobial disk susceptibility tests, 4th ed. Approved standard. National Committee for Clinical Laboratory Standards, Villanova, Pa.
24. National Committee for Clinical Laboratory Standards. 1990. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd ed. Approved standard. National Committee for Clinical Laboratory Standards, Villanova, Pa.
25. Niederman, M. S., J. B. Gass, Jr., G. D. Campbell, A. M. Fein, R. F. Grossman, L. A. Mandell, T. J. Marrie, G. A. Sarosi, A. Torres, and V. L. Yu. 1993. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am. Rev. Respir. Dis. 148:1418-1426.
26. Poirier, R. 1991. Comparative study of clarithromycin and roxithromycin in the treatment of community-acquired pneumonia. J. Antimicrob. Chemother. 27(Suppl. A):109-116.
27. U.S. Bureau of the Census. 1995. Statistical abstract of the United States, 115th ed. U.S. Government Printing Office, Washington, D.C.
28. Williams, D., M. Perri, and M. J. Zervos. 1994. Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 13:293-298.